D. Bartels

Tara L. Kieffer, C. Sarrazin, L. Gritz, 2014, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Modeling population heterogeneity in viral dynamics for chronic hepatitis C infection: Insights from Phase 3 telaprevir clinical studies

E. Haseltine, J. Tolsma, V. Garg, 2015, Journal of Pharmacokinetics and Pharmacodynamics.

Genotypic and Phenotypic Analyses of Hepatitis C Virus Variants Observed in Clinical Studies of VX-222, a Nonnucleoside NS5B Polymerase Inhibitor

Tara L. Kieffer, B. G. Rao, O. Nicolas, 2014, Antimicrobial Agents and Chemotherapy.

Phenotypic and Structural Analyses of Hepatitis C Virus NS3 Protease Arg155 Variants

A. Kwong, B. G. Rao, L. Swenson, 2007, Journal of Biological Chemistry.

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir.

Tara L. Kieffer, H. Chu, A. Kwong, 2007, Gastroenterology.

PHENOTYPIC AND STRUCTURAL ANALYSES OF HCV NS3 PROTEASE ARG 155 VARIANTS: SENSITIVITY TO TELAPREVIR (VX-950) AND INTERFERON ALPHA

A. Kwong, B. G. Rao, L. Swenson, 2007 .

Dual Targeting of GyrB and ParE by a Novel Aminobenzimidazole Class of Antibacterial Compounds

P. Charifson, T. Grossman, E. Olson, 2006, Antimicrobial Agents and Chemotherapy.

Phenotypic Characterization of Resistant Val36 Variants of Hepatitis C Virus NS3-4A Serine Protease

H. Chu, A. Kwong, B. G. Rao, 2007, Antimicrobial Agents and Chemotherapy.

Hepatitis C Virus Variants with Decreased Sensitivity to Direct-Acting Antivirals (DAAs) Were Rarely Observed in DAA-Naive Patients prior to Treatment

Tara L. Kieffer, A. Kwong, D. Takemoto, 2012, Journal of Virology.

12 Wild-type HCV NS3 protease re-emerges during follow-up after 14 days of dosing with VX-950 in patients with genotype 1 HCV

A. Kwong, S. Zeuzem, C. Sarrazin, 2006 .

Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects.

Tara L. Kieffer, A. Kwong, D. Bartels, 2008, The Journal of infectious diseases.

Modeling Viral Evolutionary Dynamics after Telaprevir-Based Treatment

Eric L. Haseltine, Andrew Davis, Tara L. Kieffer, 2014, PLoS Comput. Biol..

1184 CHARACTERIZATION OF HCV VARIANTS IN GENOTYPE 1 TREATMENT-NAIVE PATIENTS ADMINISTERED THE COMBINATION OF TVR AND VX-222 IN DUAL ARMS OF ZENITH STUDY

A. Bisceglie, D. Bartels, M. Koziel, 2012 .

Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: Results from the REALIZE trial

Tara L. Kieffer, S. Zeuzem, J. Sullivan, 2012, Hepatology.

T-24 Retreatment with telaprevir/Peg-IFN/RBV after a short exposure to telaprevir in Phase I studies: interim results from a Phase IIIb rollover trial (C219)

S. Zeuzem, C. Sarrazin, D. Bartels, 2012 .

Erf2, a Novel Gene Product That Affects the Localization and Palmitoylation of Ras2 in Saccharomyces cerevisiae

R. Deschenes, D. Bartels, Xiangwen Dong, 1999, Molecular and Cellular Biology.

Compensatory substitutions in the HCV NS3/4A protease cleavage sites are not observed in patients treated unsuccessfully with telaprevir combination treatment

A. Kwong, J. Sullivan, D. Bartels, 2012, Virology Journal.

Development of a sensitive RT-PCR method for amplifying and sequencing near full-length HCV genotype 1 RNA from patient samples

A. Kwong, J. Lippke, D. Bartels, 2013, Virology Journal.

55 FUTILITY RULES IN TELAPREVIR COMBINATION TREATMENT

L. Gritz, D. Bartels, I. Jacobson, 2012 .

Palmitoylation and Plasma Membrane Localization of Ras2p by a Nonclassical Trafficking Pathway in Saccharomyces cerevisiae

R. Deschenes, D. Bartels, Lihong Zhao, 2003, Molecular and Cellular Biology.

Phenotypic Characterization of Resistant Val 36 Variants of Hepatitis C Virus NS3-4A Serine Protease (cid:1)

H. Chu, A. Kwong, B. G. Rao, 2007 .

Futility rules for telaprevir combination treatment for patients with hepatitis C virus infection.

Tara L. Kieffer, L. Gritz, D. Bartels, 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[12] TELAPREVIR (VX-950) IS A POTENT INHIBITOR OF HCV NS3 PROTEASES DERIVED FROM GENOTYPE NON-1 HCV-INFECTED PATIENTS

A. Kwong, D. Bartels, B. Hanzelka, 2007 .